dalteparin has been researched along with Critical Illness in 75 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Critical Illness: A disease or state in which death is possible or imminent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the efficacy and safety of betrixaban for venous thromboembolism (VTE) prophylaxis among critically ill patients." | 9.30 | Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. ( Chi, G; Cohen, AT; Gibson, CM; Goldhaber, SZ; Harrington, RA; Hernandez, AF; Hull, RD; Jafarizade, M; Kahe, F; Kalayci, A; Liu, Y; Sharfaei, S, 2019) |
| " We aimed to perform a competing risk analysis to assess the efficacy of the low molecular weight heparin dalteparin versus unfractionated heparin (UFH) in venous thromboembolism (VTE) in medical-surgical critically ill patients, taking death as a competing risk." | 9.20 | Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients. ( Arabi, YM; Bellomo, R; Cook, DJ; Cooper, DJ; Crowther, M; Ferguson, ND; Finfer, S; Guyatt, G; Heels-Ansdell, D; Holbrook, A; Lamontagne, F; Levine, MAH; Li, G; Thabane, L; Walter, SD, 2015) |
| " To challenge this premise, we evaluated if deep vein thrombosis (DVT) prophylaxis with dalteparin sodium confers an excessive anticoagulant effect in critically ill patients with severe renal insufficiency." | 9.13 | Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. ( Albert, M; Anderson, D; Cook, D; Crowther, M; Douketis, J; Fowler, R; Freitag, A; Geerts, W; Granton, J; Guyatt, G; Hébert, P; Heels-Ansdell, D; Marshall, J; Meade, M; Pagliarello, G; Rabbat, C; Skrobik, Y; Zytaruk, N, 2008) |
| " A multicenter blinded, randomized trial compared the effectiveness of the most common pharmocoprevention strategies, unfractionated heparin (UFH) and the low-molecular-weight heparin (LMWH) dalteparin, finding no difference in the primary end point of leg deep-vein thrombosis but a reduced rate of pulmonary embolus and heparin-induced thrombocytopenia among critically ill medical-surgical patients who received dalteparin." | 7.80 | Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. ( Arabi, Y; Cade, JF; Chan, B; Cook, D; Cooper, J; Dodek, P; Doig, CJ; Ferguson, ND; Finfer, S; Fowler, RA; Geerts, W; Gould, MK; Guyatt, G; Hall, R; Heels-Ansdell, D; Jacka, MJ; Klinger, JR; Krahn, M; Marshall, JC; McIntyre, L; Mehta, S; Mittmann, N; Muscedere, J; Orford, N; Ormanidhi, O; Pinto, R; Qushmaq, I; Rocha, MG; Seppelt, I; Skrobik, YK; Sud, S; Vlahakis, N, 2014) |
| "In a multicenter, open-label, prospective cohort study of critically ill patients with severe acute or chronic renal insufficiency or dialysis receiving subcutaneous dalteparin 5,000 IU once daily, we estimated the prevalence of proximal DVT by screening compression venous ultrasound of the lower limbs within 48 hours of ICU admission." | 7.74 | Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. ( Albert, M; Cook, D; Crowther, M; Douketis, J; Fowler, R; Freitag, A; Friedrich, J; Geerts, W; Granton, J; Guyatt, G; Hebert, P; Heels-Ansdell, D; Karachi, T; Meade, M; Pagliarello, G; Rabbat, C; Skrobik, Y; Zytaruk, N, 2008) |
| "The objective of this study was to investigate the pharmacodynamic parameters of dalteparin in patients with renal insufficiency under intensive care." | 7.73 | Monitoring of subcutaneous dalteparin in patients with renal insufficiency under intensive care: an observational study. ( Kani, C; Maggina, N; Markantonis, SL; Nicolaou, C, 2006) |
| " We assessed for an effect modification of thromboprophylaxis (dalteparin or unfractionated heparin [UFH]) by sex on thrombotic (deep venous thrombosis [DVT], pulmonary embolism [PE], VTE) and mortality outcomes in a secondary analysis of the Prophylaxis for Thromboembolism in Critical Care Trial (PROTECT)." | 5.69 | Sex differences in thromboprophylaxis of the critically ill: a secondary analysis of a randomized trial. ( Bhuptani, P; Burns, KEA; Cook, DJ; Crowther, MA; Finfer, S; Heels-Ansdell, D; Kahn, SR; Lauzier, F; Mehta, S; Ostermann, M; Thabane, L, 2023) |
| "To assess the efficacy and safety of betrixaban for venous thromboembolism (VTE) prophylaxis among critically ill patients." | 5.30 | Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. ( Chi, G; Cohen, AT; Gibson, CM; Goldhaber, SZ; Harrington, RA; Hernandez, AF; Hull, RD; Jafarizade, M; Kahe, F; Kalayci, A; Liu, Y; Sharfaei, S, 2019) |
| " We aimed to perform a competing risk analysis to assess the efficacy of the low molecular weight heparin dalteparin versus unfractionated heparin (UFH) in venous thromboembolism (VTE) in medical-surgical critically ill patients, taking death as a competing risk." | 5.20 | Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients. ( Arabi, YM; Bellomo, R; Cook, DJ; Cooper, DJ; Crowther, M; Ferguson, ND; Finfer, S; Guyatt, G; Heels-Ansdell, D; Holbrook, A; Lamontagne, F; Levine, MAH; Li, G; Thabane, L; Walter, SD, 2015) |
| " To challenge this premise, we evaluated if deep vein thrombosis (DVT) prophylaxis with dalteparin sodium confers an excessive anticoagulant effect in critically ill patients with severe renal insufficiency." | 5.13 | Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. ( Albert, M; Anderson, D; Cook, D; Crowther, M; Douketis, J; Fowler, R; Freitag, A; Geerts, W; Granton, J; Guyatt, G; Hébert, P; Heels-Ansdell, D; Marshall, J; Meade, M; Pagliarello, G; Rabbat, C; Skrobik, Y; Zytaruk, N, 2008) |
| " Conservative treatment included: (a) weight-adjusted bemiparin plus six hours/day intravenous iloprost for 28 days, (b) aspirin (100 mg/day) plus cilostazol (100 mg twice/day) after discharge, and (c) strict recommendations/monitoring for smoking cessation." | 3.85 | Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia. ( Anastasiadou, C; Galyfos, G; Geropapas, G; Giannakakis, S; Kastrisios, G; Kerasidis, S; Maltezos, C; Papacharalampous, G; Papapetrou, A; Sachmpazidis, I, 2017) |
| " A multicenter blinded, randomized trial compared the effectiveness of the most common pharmocoprevention strategies, unfractionated heparin (UFH) and the low-molecular-weight heparin (LMWH) dalteparin, finding no difference in the primary end point of leg deep-vein thrombosis but a reduced rate of pulmonary embolus and heparin-induced thrombocytopenia among critically ill medical-surgical patients who received dalteparin." | 3.80 | Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. ( Arabi, Y; Cade, JF; Chan, B; Cook, D; Cooper, J; Dodek, P; Doig, CJ; Ferguson, ND; Finfer, S; Fowler, RA; Geerts, W; Gould, MK; Guyatt, G; Hall, R; Heels-Ansdell, D; Jacka, MJ; Klinger, JR; Krahn, M; Marshall, JC; McIntyre, L; Mehta, S; Mittmann, N; Muscedere, J; Orford, N; Ormanidhi, O; Pinto, R; Qushmaq, I; Rocha, MG; Seppelt, I; Skrobik, YK; Sud, S; Vlahakis, N, 2014) |
| "The objective of this report is to describe the roles, responsibilities and recommendations of a 3-member Event Adjudication Committee (EAC) and a 5-member data monitoring committee (DMC) for a prospective multicenter observational study of critically ill patients with renal insufficiency examining the bioaccumulation and bleeding risk associated with dalteparin thromboprophylaxis." | 3.75 | Event adjudication and data monitoring in an intensive care unit observational study of thromboprophylaxis. ( Cook, D; Crowther, M; Douketis, J; Lee, A; Linkins, L; Marshall, JC; Meade, M; O'Donnell, M; Patel, R; Rabbat, C; Sinuff, T; Thabane, L; Treleaven, D; Zytaruk, N, 2009) |
| "In a multicenter, open-label, prospective cohort study of critically ill patients with severe acute or chronic renal insufficiency or dialysis receiving subcutaneous dalteparin 5,000 IU once daily, we estimated the prevalence of proximal DVT by screening compression venous ultrasound of the lower limbs within 48 hours of ICU admission." | 3.74 | Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. ( Albert, M; Cook, D; Crowther, M; Douketis, J; Fowler, R; Freitag, A; Friedrich, J; Geerts, W; Granton, J; Guyatt, G; Hebert, P; Heels-Ansdell, D; Karachi, T; Meade, M; Pagliarello, G; Rabbat, C; Skrobik, Y; Zytaruk, N, 2008) |
| "The objective of this study was to investigate the pharmacodynamic parameters of dalteparin in patients with renal insufficiency under intensive care." | 3.73 | Monitoring of subcutaneous dalteparin in patients with renal insufficiency under intensive care: an observational study. ( Kani, C; Maggina, N; Markantonis, SL; Nicolaou, C, 2006) |
| " Pharmacokinetic profiles were significantly different." | 3.11 | Pharmacokinetic profiles of intravenous versus subcutaneous administration of low molecular weight heparin for thromboprophylaxis in critically ill patients: A randomized controlled trial. ( De Schryver, N; Eeckhoudt, S; Gérard, L; Laterre, PF; Serck, N; Wittebole, X, 2022) |
| " In the IV group, anti-Xa decrease half-life was 1." | 2.94 | Pharmacokinetic Comparison of Subcutaneous and Intravenous Nadroparin Administration for Thromboprophylaxis in Critically Ill Patients on Vasopressors. ( Cihlar, R; Papiez, A; Penka, M; Sramek, V; Suk, P, 2020) |
| "Dalteparin was associated with fewer study drug-attributable HIT-related events (P = ." | 2.78 | Heparin-induced thrombocytopenia in medical surgical critical illness. ( Bersten, AD; Cook, DJ; Crowther, MA; Crozier, TM; Davies, AR; Ernest, D; Hall, RI; Heels-Ansdell, D; Marshall, JC; McIntyre, L; Mehta, S; Poirier, G; Rocha, MG; Sheppard, JI; Vlahakis, NE; Warkentin, TE; Wood, GG, 2013) |
| "Venous thromboembolism is a frequent complication in critically ill patients that has a negative impact on patient outcomes." | 2.77 | Bioactivity of enoxaparin in critically ill patients with normal renal function. ( Gouya, G; Heinz, G; Kapiotis, S; Locker, G; Madl, C; Palkovits, S; Stella, A; Wolzt, M, 2012) |
| "In high risk critically ill patients citrate based anticoagulation for CVVH is safe in terms of bleeding complications and transfusion requirements." | 2.72 | Safety of citrate based hemofiltration in critically ill patients at high risk for bleeding: a comparison with nadroparin. ( Boerma, EC; Kingma, WP; Postma, SR; Van der Voort, PH; Van Roon, EN, 2006) |
| " Following is an overview of major insights from the prophylaxis in Medical patients with Enoxaparin (MEDENOX) trial, which was undertaken to evaluate the efficacy of 2 dosage regimens of the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism in acutely ill medical patients." | 2.69 | Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. ( Turpie, AG, 2000) |
| "Best practice in thromboprophylaxis for trauma patients will remain on the basis of recommendations until definitive risk-benefit ratios are determined to justify the use of various mechanical and pharmacological measures, in combination or alone." | 2.44 | Postinjury thromboprophylaxis. ( Balogh, Z; Bendinelli, C, 2008) |
| " Despite existing population pharmacokinetic (PK) models for nadroparin in literature, the population PK of nadroparin in COVID-19 ICU patients is unknown." | 1.91 | Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients. ( Endeman, H; Hunfeld, NGM; Kruip, MJHA; Preijers, T; Romano, LGR, 2023) |
| "7-280) and relative bioavailability of 40." | 1.91 | Low and Highly Variable Exposure to Prophylactic LMWH Nadroparin in Critically Ill Patients: Back to the Drawing Board for Prophylactic Dosing? ( Diepstraten, J; Kruip, MJHA; Ter Heine, R; van der Heiden, PLJ; van Rongen, A; Zijlstra, MP, 2023) |
| " Anti-Xa activity in critically ill patients achieved with standard dosing of low-molecular-weight heparins (LMWH) is often below the target of 0." | 1.72 | Fixed-dose enoxaparin provides efficient DVT prophylaxis in mixed ICU patients despite low anti-Xa levels: A prospective observational cohort study. ( Benes, J; Cerny, V; Jobanek, J; Skulec, R, 2022) |
| " Anti-Xa activities from consecutive patients with laboratory-confirmed SARS-CoV-2 infection treated with enoxaparin for the prevention or the treatment of venous thrombosis were used to develop a population pharmacokinetic model using non-linear mixed effects techniques." | 1.62 | Pharmacokinetics of enoxaparin in COVID-19 critically ill patients. ( Bauters, A; Caplan, M; Delavenne, X; Dupont, A; Goutay, J; Jean, L; Lanoiselée, J; Levy, L; Poissy, J; Susen, S; Zufferey, PJ, 2021) |
| " Thromboprophylaxis dosage was based on local standardized recommendations, not on degree of critical illness or risk of thrombosis." | 1.56 | Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients. ( Cronhjort, M; Dahlberg, M; Everhov, ÅH; Grip, J; Günther, M; Hollenberg, J; Järnbert-Pettersson, H; Jonmarker, S; Litorell, J; Schandl, A; Söderberg, M; Stackelberg, O, 2020) |
| "Our study suggests that anticoagulation with IV enoxaparin infused over 30 minutes is a safe and an equally effective alternative to subcutaneous enoxaparin in critically ill infants and children." | 1.46 | IV Versus Subcutaneous Enoxaparin in Critically Ill Infants and Children: Comparison of Dosing, Anticoagulation Quality, Efficacy, and Safety Outcomes. ( Alfares, FA; Berger, JT; Chounoune, R; Corcoran, J; Diab, YA; Endicott, KM; Ferrell, B; Nath, DS; Ramakrishnan, K; Rooney, S; Shankar, V; Zurakowski, D, 2017) |
| " However, evidence suggests decreased bioavailability of enoxaparin in critically ill patients." | 1.42 | Prospective Evaluation of Weight-Based Prophylactic Enoxaparin Dosing in Critically Ill Trauma Patients: Adequacy of AntiXa Levels Is Improved. ( Becher, RD; Borgerding, EM; Farrah, JP; Kilgo, P; Lauer, C; Miller, PR; Nunez, JM; Rebo, GJ; Stirparo, JJ, 2015) |
| "Age, critical illness, and timing of AT3 had no effect on time to therapeutic anti-Xa levels." | 1.40 | Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis. ( Corder, A; Held, K; Oschman, A, 2014) |
| "As major bleeding has modifiable risk factors and is associated with in-hospital mortality, strategies to mitigate these factors should be evaluated in critically ill patients." | 1.39 | Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis. ( Albert, M; Arnold, DM; Ashley, BJ; Cook, D; Crowther, M; Dodek, P; Finfer, S; Fowler, R; Heels-Ansdell, D; Karachi, T; Khwaja, K; Lauzier, F; Lopes, RD; McIntyre, L; Nates, JL; Ostermann, M; Rabbat, C; Skrobik, Y; Zarychanski, R; Zytaruk, N, 2013) |
| "In the study, prophylactic SC enoxaparin in critically ill patients at the current 30 mg SC twice daily dosage attained an anti-Xa level more than 0." | 1.37 | Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients. ( Albert, M; Blais, L; Boulanger, I; Champagne, MC; Vincent, PD; Williamson, DR; Zikos, T, 2011) |
| "Venous thromboembolism is a relatively frequently occurring complication in critically ill patients admitted to the ICU despite prophylactic treatment with subcutaneous low molecular weight heparin." | 1.36 | Adequate thromboprophylaxis in critically ill patients. ( Levi, M, 2010) |
| "8 dosage adjustments was needed." | 1.36 | Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit? ( Berry, D; Chrysostomou, C; Gunawardena, S; Krallman, S; Morell, VO; Munoz, R; Orr, R; Sanchez de Toledo, J; Shiderly, D; Sonderman, S; Wang, L; Wearden, P, 2010) |
| " Evidence suggests inconsistent bioavailability in intensive care unit (ICU) patients." | 1.35 | Thrombelastography versus AntiFactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients. ( Cho, SD; Morris, MS; Schreiber, MA; Underwood, SJ; Van, PY; Watters, JM, 2009) |
| " However, little pharmacodynamic data are available for determining the appropriate dosing and monitoring (by anti-Factor Xa levels) of intravenous enoxaparin." | 1.35 | Experience with intravenous enoxaparin in critically ill infants and children. ( Crary, SE; Journeycake, JM; Van Orden, H, 2008) |
| " The efficacy of daily dosing in critically ill patients is unknown." | 1.33 | Optimal dose of enoxaparin in critically ill trauma and surgical patients. ( Abrams, JE; Rutherford, EJ; Schooler, WG; Skeete, DA; Sredzienski, E, 2005) |
| "Two cohorts of critically ill multiple trauma patients were enrolled in this study: A (nonedematous) and B (edematous, defined as the presence of peripheral edema and an increase in body weight of > or =10 kg)." | 1.33 | Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients. ( Beres, J; Forrest, A; Haas, CE; Ma, Q; Mihalko, W; Nelsen, JL; Raghavendran, K, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.67) | 18.2507 |
| 2000's | 20 (26.67) | 29.6817 |
| 2010's | 30 (40.00) | 24.3611 |
| 2020's | 23 (30.67) | 2.80 |
| Authors | Studies |
|---|---|
| De Schryver, N | 1 |
| Serck, N | 1 |
| Eeckhoudt, S | 1 |
| Laterre, PF | 1 |
| Wittebole, X | 1 |
| Gérard, L | 1 |
| Eck, RJ | 1 |
| van de Leur, JJCM | 1 |
| Wiersema, R | 1 |
| Cox, EGM | 1 |
| Bult, W | 1 |
| Spanjersberg, AJ | 1 |
| van der Horst, ICC | 1 |
| Lukens, MV | 1 |
| Gans, ROB | 1 |
| Meijer, K | 1 |
| Keus, F | 1 |
| Romano, LGR | 2 |
| Hunfeld, NGM | 2 |
| Kruip, MJHA | 3 |
| Endeman, H | 2 |
| Preijers, T | 2 |
| Diepstraten, J | 1 |
| van Rongen, A | 1 |
| Zijlstra, MP | 1 |
| van der Heiden, PLJ | 1 |
| Ter Heine, R | 2 |
| Cihlar, R | 1 |
| Sramek, V | 1 |
| Papiez, A | 1 |
| Penka, M | 1 |
| Suk, P | 1 |
| Buter, H | 1 |
| Koopmans, M | 2 |
| van der Voort, PHJ | 1 |
| Crowther, MA | 3 |
| Cook, DJ | 4 |
| Oudemans-van Straaten, HM | 2 |
| Bosman, RJ | 1 |
| van der Voort, PH | 3 |
| Wester, JP | 2 |
| van der Spoel, JI | 1 |
| Dijksman, LM | 1 |
| Zandstra, DF | 1 |
| van Schilfgaarde, M | 1 |
| Molenaar, PJ | 1 |
| Leyte, A | 1 |
| Postma, SR | 2 |
| Kingma, WP | 2 |
| Boerma, EC | 2 |
| Van Roon, EN | 1 |
| de Heide, LJ | 1 |
| Bakker, AJ | 1 |
| Kobza, II | 1 |
| Galyfos, G | 1 |
| Kerasidis, S | 1 |
| Kastrisios, G | 1 |
| Giannakakis, S | 1 |
| Sachmpazidis, I | 1 |
| Anastasiadou, C | 1 |
| Geropapas, G | 1 |
| Papapetrou, A | 1 |
| Papacharalampous, G | 1 |
| Maltezos, C | 1 |
| Araldi, RP | 1 |
| Prezoto, BC | 1 |
| Gonzaga, V | 1 |
| Policiquio, B | 1 |
| Mendes, TB | 1 |
| D'Amélio, F | 1 |
| Vigerelli, H | 1 |
| Viana, M | 1 |
| Valverde, CW | 1 |
| Pagani, E | 1 |
| Kerkis, I | 1 |
| Bösch, J | 1 |
| Rugg, C | 1 |
| Schäfer, V | 1 |
| Lichtenberger, P | 1 |
| Staier, N | 1 |
| Treichl, B | 1 |
| Rajsic, S | 1 |
| Peer, A | 1 |
| Schobersberger, W | 1 |
| Fries, D | 1 |
| Bachler, M | 1 |
| Wang, C | 1 |
| Ning, YC | 1 |
| Song, LP | 1 |
| Li, PJ | 1 |
| Wang, FH | 1 |
| Ding, MX | 1 |
| Jiang, L | 1 |
| Wang, M | 1 |
| Pei, QQ | 1 |
| Hu, SM | 1 |
| Wang, H | 1 |
| Mahlab-Guri, K | 1 |
| Otman, MS | 1 |
| Replianski, N | 1 |
| Rosenberg-Bezalel, S | 1 |
| Rabinovich, I | 1 |
| Sthoeger, Z | 1 |
| Vahtera, A | 1 |
| Szanto, T | 1 |
| Lassila, R | 1 |
| Valkonen, M | 1 |
| Sivula, M | 1 |
| Huhtala, H | 1 |
| Pettilä, V | 1 |
| Kuitunen, A | 1 |
| Bikdeli, B | 1 |
| Talasaz, AH | 1 |
| Rashidi, F | 1 |
| Sharif-Kashani, B | 1 |
| Farrokhpour, M | 1 |
| Bakhshandeh, H | 1 |
| Sezavar, H | 1 |
| Dabbagh, A | 1 |
| Beigmohammadi, MT | 1 |
| Payandemehr, P | 1 |
| Yadollahzadeh, M | 1 |
| Riahi, T | 1 |
| Khalili, H | 1 |
| Jamalkhani, S | 1 |
| Rezaeifar, P | 1 |
| Abedini, A | 1 |
| Lookzadeh, S | 1 |
| Shahmirzaei, S | 1 |
| Tahamtan, O | 1 |
| Matin, S | 1 |
| Amin, A | 1 |
| Parhizgar, SE | 1 |
| Jimenez, D | 1 |
| Gupta, A | 1 |
| Madhavan, MV | 1 |
| Parikh, SA | 1 |
| Monreal, M | 1 |
| Hadavand, N | 1 |
| Hajighasemi, A | 1 |
| Maleki, M | 1 |
| Sadeghian, S | 1 |
| Mohebbi, B | 1 |
| Piazza, G | 1 |
| Kirtane, AJ | 1 |
| Lip, GYH | 1 |
| Krumholz, HM | 1 |
| Goldhaber, SZ | 2 |
| Sadeghipour, P | 1 |
| Atallah, B | 1 |
| Sadik, ZG | 1 |
| Salem, N | 1 |
| El Nekidy, WS | 1 |
| Almahmeed, W | 1 |
| Park, WM | 1 |
| Cherfan, A | 1 |
| Hamed, F | 1 |
| Mallat, J | 1 |
| Faustino, EVS | 2 |
| Shabanova, V | 2 |
| Raffini, LJ | 2 |
| Kandil, SB | 2 |
| Li, S | 2 |
| Pinto, MG | 2 |
| Cholette, JM | 2 |
| Hanson, SJ | 2 |
| Nellis, ME | 2 |
| Silva, CT | 2 |
| Chima, R | 1 |
| Sharathkumar, A | 1 |
| Thomas, KA | 1 |
| McPartland, T | 2 |
| Tala, JA | 2 |
| Spinella, PC | 2 |
| Marshall, AM | 1 |
| Trussell, TM | 1 |
| Yee, AM | 1 |
| Malone, MP | 1 |
| Benes, J | 1 |
| Skulec, R | 1 |
| Jobanek, J | 1 |
| Cerny, V | 1 |
| Zufferey, PJ | 1 |
| Dupont, A | 1 |
| Lanoiselée, J | 1 |
| Bauters, A | 1 |
| Poissy, J | 1 |
| Goutay, J | 1 |
| Jean, L | 1 |
| Caplan, M | 1 |
| Levy, L | 1 |
| Susen, S | 1 |
| Delavenne, X | 1 |
| Parker, RI | 1 |
| Chi, G | 1 |
| Gibson, CM | 1 |
| Kalayci, A | 1 |
| Cohen, AT | 1 |
| Hernandez, AF | 1 |
| Hull, RD | 1 |
| Kahe, F | 1 |
| Jafarizade, M | 1 |
| Sharfaei, S | 1 |
| Liu, Y | 1 |
| Harrington, RA | 1 |
| Bertoletti, L | 1 |
| Murgier, M | 1 |
| Stelfox, HT | 1 |
| Lim, SY | 1 |
| Jeon, K | 1 |
| Kim, HJ | 1 |
| Kim, SM | 1 |
| Song, J | 1 |
| Ha, JM | 1 |
| Um, SW | 1 |
| Koh, WJ | 1 |
| Chung, MP | 1 |
| Kim, H | 1 |
| Kwon, OJ | 1 |
| Suh, GY | 1 |
| Robinson, S | 2 |
| Zincuk, A | 2 |
| Larsen, UL | 2 |
| Ekstrøm, C | 2 |
| Nybo, M | 1 |
| Rasmussen, B | 1 |
| Toft, P | 2 |
| Corder, A | 1 |
| Held, K | 1 |
| Oschman, A | 1 |
| Nunez, JM | 1 |
| Becher, RD | 1 |
| Rebo, GJ | 1 |
| Farrah, JP | 1 |
| Borgerding, EM | 1 |
| Stirparo, JJ | 1 |
| Lauer, C | 1 |
| Kilgo, P | 1 |
| Miller, PR | 1 |
| Helviz, Y | 1 |
| Dzigivker, I | 1 |
| Raveh-Brawer, D | 1 |
| Hersch, M | 1 |
| Zevin, S | 1 |
| Einav, S | 1 |
| Castellucci, LA | 1 |
| Shaw, J | 1 |
| Giulivi, A | 1 |
| Edwards, C | 1 |
| Carrier, M | 1 |
| Patel, R | 2 |
| Hanify, JM | 1 |
| Dupree, LH | 1 |
| Johnson, DW | 1 |
| Ferreira, JA | 1 |
| Diab, YA | 1 |
| Ramakrishnan, K | 1 |
| Ferrell, B | 1 |
| Chounoune, R | 1 |
| Alfares, FA | 1 |
| Endicott, KM | 1 |
| Rooney, S | 1 |
| Corcoran, J | 1 |
| Zurakowski, D | 1 |
| Berger, JT | 1 |
| Shankar, V | 1 |
| Nath, DS | 1 |
| Crary, SE | 1 |
| Van Orden, H | 1 |
| Journeycake, JM | 1 |
| Bendinelli, C | 1 |
| Balogh, Z | 1 |
| Van, PY | 1 |
| Cho, SD | 1 |
| Underwood, SJ | 1 |
| Morris, MS | 1 |
| Watters, JM | 1 |
| Schreiber, MA | 1 |
| De, A | 1 |
| Roy, P | 1 |
| Garg, VK | 1 |
| Pandey, NK | 1 |
| Sanchez de Toledo, J | 1 |
| Gunawardena, S | 1 |
| Munoz, R | 1 |
| Orr, R | 1 |
| Berry, D | 1 |
| Sonderman, S | 1 |
| Krallman, S | 1 |
| Shiderly, D | 1 |
| Wang, L | 1 |
| Wearden, P | 1 |
| Morell, VO | 1 |
| Chrysostomou, C | 1 |
| Levi, M | 1 |
| Scholey, GM | 1 |
| Saayman, AG | 1 |
| Hingston, CD | 1 |
| Wise, MP | 1 |
| Vincent, PD | 1 |
| Albert, M | 4 |
| Champagne, MC | 1 |
| Zikos, T | 1 |
| Boulanger, I | 1 |
| Blais, L | 1 |
| Williamson, DR | 1 |
| Gouya, G | 1 |
| Palkovits, S | 1 |
| Kapiotis, S | 1 |
| Madl, C | 1 |
| Locker, G | 1 |
| Stella, A | 1 |
| Wolzt, M | 1 |
| Heinz, G | 2 |
| Priglinger, U | 1 |
| Delle Karth, G | 1 |
| Geppert, A | 1 |
| Joukhadar, C | 1 |
| Graf, S | 1 |
| Berger, R | 1 |
| Hülsmann, M | 1 |
| Spitzauer, S | 1 |
| Pabinger, I | 1 |
| Freedman, MD | 1 |
| Kavanagh, D | 1 |
| Hill, AD | 1 |
| Martin, S | 1 |
| Power, C | 1 |
| McDermott, EW | 1 |
| O'Higgins, N | 1 |
| Murphy, K | 1 |
| Rutherford, EJ | 1 |
| Schooler, WG | 1 |
| Sredzienski, E | 1 |
| Abrams, JE | 1 |
| Skeete, DA | 1 |
| Haas, CE | 1 |
| Nelsen, JL | 1 |
| Raghavendran, K | 1 |
| Mihalko, W | 1 |
| Beres, J | 1 |
| Ma, Q | 1 |
| Forrest, A | 1 |
| Burgess, JK | 1 |
| Chong, BH | 1 |
| Turpie, AG | 1 |
| van der Heijden, CDCC | 1 |
| Kooistra, EJ | 1 |
| Brüggemann, RJ | 1 |
| Walburgh Schmidt, JWJ | 1 |
| de Grouw, EPLM | 1 |
| Frenzel, T | 1 |
| Pickkers, P | 1 |
| Leentjens, J | 1 |
| Burns, KEA | 1 |
| Heels-Ansdell, D | 8 |
| Thabane, L | 3 |
| Kahn, SR | 1 |
| Lauzier, F | 2 |
| Mehta, S | 3 |
| Ostermann, M | 2 |
| Bhuptani, P | 1 |
| Finfer, S | 4 |
| Meenks, SD | 1 |
| Foudraine, NA | 1 |
| Broen, K | 1 |
| le Noble, JLML | 1 |
| Janssen, PKC | 1 |
| Dahlberg, J | 1 |
| Eriksen, C | 1 |
| Robertsen, A | 1 |
| Beitland, S | 1 |
| Stattin, K | 1 |
| Lipcsey, M | 1 |
| Andersson, H | 1 |
| Pontén, E | 1 |
| Bülow Anderberg, S | 1 |
| Gradin, A | 1 |
| Larsson, A | 1 |
| Lubenow, N | 1 |
| von Seth, M | 1 |
| Rubertsson, S | 1 |
| Hultström, M | 1 |
| Frithiof, R | 1 |
| Jonmarker, S | 1 |
| Hollenberg, J | 1 |
| Dahlberg, M | 1 |
| Stackelberg, O | 1 |
| Litorell, J | 1 |
| Everhov, ÅH | 1 |
| Järnbert-Pettersson, H | 1 |
| Söderberg, M | 1 |
| Grip, J | 1 |
| Schandl, A | 1 |
| Günther, M | 1 |
| Cronhjort, M | 1 |
| Warkentin, TE | 2 |
| Sheppard, JI | 1 |
| Marshall, JC | 3 |
| McIntyre, L | 3 |
| Rocha, MG | 2 |
| Davies, AR | 1 |
| Bersten, AD | 1 |
| Crozier, TM | 1 |
| Ernest, D | 1 |
| Vlahakis, NE | 2 |
| Hall, RI | 1 |
| Wood, GG | 1 |
| Poirier, G | 1 |
| Arnold, DM | 1 |
| Rabbat, C | 4 |
| Zarychanski, R | 1 |
| Dodek, P | 2 |
| Ashley, BJ | 1 |
| Khwaja, K | 1 |
| Skrobik, Y | 3 |
| Fowler, R | 3 |
| Nates, JL | 1 |
| Karachi, T | 2 |
| Lopes, RD | 1 |
| Zytaruk, N | 5 |
| Crowther, M | 6 |
| Cook, D | 6 |
| Fowler, RA | 1 |
| Mittmann, N | 1 |
| Geerts, W | 4 |
| Gould, MK | 1 |
| Guyatt, G | 5 |
| Krahn, M | 1 |
| Pinto, R | 1 |
| Chan, B | 1 |
| Ormanidhi, O | 1 |
| Arabi, Y | 1 |
| Qushmaq, I | 2 |
| Hall, R | 1 |
| Ferguson, ND | 2 |
| Doig, CJ | 1 |
| Muscedere, J | 1 |
| Jacka, MJ | 1 |
| Klinger, JR | 1 |
| Vlahakis, N | 1 |
| Orford, N | 1 |
| Seppelt, I | 1 |
| Skrobik, YK | 1 |
| Sud, S | 1 |
| Cade, JF | 1 |
| Cooper, J | 1 |
| Pastores, SM | 1 |
| DeSancho, MT | 1 |
| Li, G | 1 |
| Levine, MAH | 1 |
| Holbrook, A | 1 |
| Lamontagne, F | 1 |
| Walter, SD | 1 |
| Arabi, YM | 1 |
| Bellomo, R | 1 |
| Cooper, DJ | 2 |
| Douketis, J | 3 |
| Meade, M | 4 |
| Granton, J | 2 |
| Hébert, P | 2 |
| Pagliarello, G | 2 |
| Marshall, J | 1 |
| Freitag, A | 2 |
| Anderson, D | 1 |
| Sinuff, T | 1 |
| Lee, A | 1 |
| O'Donnell, M | 1 |
| Linkins, L | 1 |
| Treleaven, D | 1 |
| Walter, S | 1 |
| Vallance, S | 1 |
| Rocha, M | 1 |
| Berwanger, O | 1 |
| Smythe, MA | 1 |
| Koerber, JM | 1 |
| Esterbrook, G | 1 |
| Hart, S | 1 |
| Davidson, BL | 1 |
| Knight, DJ | 1 |
| Selwyn, D | 1 |
| Girling, K | 1 |
| Klerk, CP | 1 |
| Smorenburg, SM | 1 |
| Büller, HR | 1 |
| Kani, C | 1 |
| Markantonis, SL | 1 |
| Nicolaou, C | 1 |
| Maggina, N | 1 |
| Friedrich, J | 1 |
| Villié, P | 1 |
| Noël, N | 1 |
| Ackermann, F | 1 |
| Rivoisy, C | 1 |
| Le Pavec, J | 1 |
| Savale, L | 1 |
| Goujard, C | 1 |
| Rocher, L | 1 |
| Lambotte, O | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intravenous Versus Subcutaneous Administration of Low Molecular Weight Heparin for Thromboprophylaxis in Critically Ill Patients: a Randomized Controlled Trial[NCT04982055] | Phase 4 | 60 participants (Actual) | Interventional | 2015-04-08 | Completed | ||
| Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration, a Randomized Controlled Trial Comparing Anticoagulation With Citrate to the Low Molecular Weight Heparin Nadroparin[NCT00286273] | Phase 4 | 215 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Simplified Regional Citrate Anticoagulation Protocols for CVVH, CVVHDF and SLED Focused on the Prevention of RRT-related Hypophosphatemia and Optimization of Acid-base Balance: a Pilot Study[NCT03976440] | 30 participants (Anticipated) | Observational | 2019-06-01 | Active, not recruiting | |||
| Nadroparin Anticoagulation for Continuous Venovenous Hemofiltration (CVVH), a Randomized Cross-over Trial Comparing Hemostasis Between Two Hemofiltration Rates[NCT00965328] | Phase 4 | 14 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Intermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19: An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19[NCT04486508] | Phase 3 | 600 participants (Actual) | Interventional | 2020-07-30 | Completed | ||
| Prevention of Central Venous Catheter-associated Thrombosis in Critically Ill Children: A Multicenter Phase 2b Trial[NCT03003390] | Phase 2 | 51 participants (Actual) | Interventional | 2017-04-05 | Terminated (stopped due to Met protocol defined stopping rule for futility) | ||
| The Prevalence and Incidence of Deep Venous Thrombosis in General ICU Patients Receiving Enoxaparine Prophylaxis[NCT03286985] | 200 participants (Actual) | Observational | 2017-09-01 | Completed | |||
| (Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients[NCT01583218] | Phase 3 | 7,513 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Prospective Randomised Study of the Effect of Vasopressors on the Anti Xa Response to Enoxaparin in Critically Ill Patients[NCT00351663] | Phase 4 | 39 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| InterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19: A Prospective Randomized Study (The IMPACT Trial)[NCT04406389] | Phase 4 | 14 participants (Actual) | Interventional | 2020-10-13 | Terminated (stopped due to Low accrual) | ||
| Norwegian Intensive Care Unit Dalteparin Effect Study[NCT01721928] | 70 participants (Actual) | Observational | 2012-12-03 | Completed | |||
| Barriers in the Process of Achieving Informed Consent From Critically Ill Patients[NCT03405766] | 70 participants (Actual) | Observational | 2018-05-02 | Completed | |||
| Uppsala Intensive Care Study of Mechanisms for Organ Dysfunction in Covid-19[NCT04316884] | 300 participants (Anticipated) | Observational | 2020-03-12 | Recruiting | |||
| Patient Characteristics, Outcome and Thromboembolic Events Among Adult Critically Ill COVID-19 Patients With Different Anticoagulant Regimes at One of the Biggest Emergency Hospitals in Northern Europe, Sweden[NCT04412304] | 166 participants (Actual) | Observational | 2020-03-06 | Completed | |||
| PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)[NCT00182143] | Phase 3 | 3,659 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Dalteparin's Influence on Renally Compromised: Anti-Ten-A Study (DIRECT)[NCT00138099] | 140 participants (Actual) | Observational | 2004-07-31 | Completed | |||
| Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses[NCT02719418] | 28 participants (Actual) | Observational | 2016-02-01 | Completed | |||
| Incidence and Characteristics of Pulmonary Embolism in COVID-19 Patients Hospitalized for Acute Respiratory Syndrome[NCT04420312] | 1,024 participants (Actual) | Observational | 2020-03-01 | Completed | |||
| Comparison of Effectiveness and Safety of Two Methods for Installing Femoral Central Venous Catheters in Pediatric Intensive Care Units : Anatomical Method vs Ultrasound in Real Time.[NCT02318940] | 99 participants (Actual) | Interventional | 2014-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Duration of stay in the hospital from the day of enrollment (NCT03003390)
Timeframe: Up to day of discharge from the hospital, an average of 18 days
| Intervention | days (Median) |
|---|---|
| Prophylaxis With Enoxaparin | 16 |
| Control Arm | 16 |
Duration of stay in the pediatric intensive care unit from the day of enrollment (NCT03003390)
Timeframe: Up to day of discharge from the pediatric intensive care unit, an average of 10 days
| Intervention | days (Median) |
|---|---|
| Prophylaxis With Enoxaparin | 12 |
| Control Arm | 8 |
Number of children in whom ultrasound was not performed. (NCT03003390)
Timeframe: Up to 24 hours after removal of CVC
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled Children | 47 |
Number of eligible children enrolled in the study. (NCT03003390)
Timeframe: Up to 24 hours after insertion of CVC
| Intervention | Participants (Count of Participants) |
|---|---|
| Eligible Children | 51 |
Number of doses of enoxaparin that were not administered. This outcome measure was only applicable to the enoxaparin arm. (NCT03003390)
Timeframe: Up to removal of CVC, an average of 6 days
| Intervention | Doses of enoxaparin (Number) |
|---|---|
| Prophylaxis With Enoxaparin | 8 |
In-hospital mortality during the subject's admission (NCT03003390)
Timeframe: Up to day of discharge from the hospital, average of 18 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Prophylaxis With Enoxaparin | 5 |
| Control Arm | 2 |
Thrombus in the central vein where the CVC was inserted that is clinically suspected then confirmed radiologically, an incidental radiologic finding, or diagnosed with the study-related active surveillance ultrasound (NCT03003390)
Timeframe: Up to removal of CVC, an average of 6 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Prophylaxis With Enoxaparin | 7 |
| Control Arm | 13 |
Bleeding that is fatal, associated with a decrease in hemoglobin by ≥2 g/dl in 24 hours, requires medical or surgical intervention to restore hemostasis, or is in the retroperitoneum, pulmonary, intracranial or central nervous system as defined by International Society of Thrombosis and Haemostasis (NCT03003390)
Timeframe: Up to 30 hours after the last enoxaparin dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Prophylaxis With Enoxaparin | 1 |
| Control Arm | 0 |
Heparin-induced thrombocytopenia that is diagnosed with a positive serotonin release assay (NCT03003390)
Timeframe: Up to removal of CVC, an average of 6 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Prophylaxis With Enoxaparin | 0 |
| Control Arm | 0 |
Thrombus in the deep vein of any extremity or PE that is clinically suspected then confirmed radiologically, an incidental radiologic finding, excluding DVT diagnosed with the study-related active surveillance ultrasound (NCT03003390)
Timeframe: Up to removal of CVC, an average of 6 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Prophylaxis With Enoxaparin | 1 |
| Control Arm | 1 |
Time to first dose of enoxaparin (NCT03003390)
Timeframe: Up to 48 hours after insertion of CVC
| Intervention | hours from insertion of CVC (Median) |
|---|---|
| Prophylaxis With Enoxaparin | 21.1 |
Time from insertion of the CVC to time that anti-Xa activity was within 0.2-0.5 IU/mL. (NCT03003390)
Timeframe: Up to removal of CVC, an average of 6 days
| Intervention | hours from insertion of CVC (Median) |
|---|---|
| Prophylaxis With Enoxaparin | 70.4 |
An established measure of coagulation status and is the best method to measure thrombin generation. It directly measures the amount of thrombin generation over time capturing the effects of natural (i.e., subject's coagulation status) and pharmacological (e.g., enoxaparin) pro- and anticoagulants. Endogenous thrombin potential is measured using thrombin generation assay. (NCT03003390)
Timeframe: Day of, day after and day 4 after insertion of the CVC
| Intervention | Nanomolar-minute (nM.min) (Median) | ||
|---|---|---|---|
| Day of CVC Insertion | Day After CVC Insertion | Day 4 After CVC Insertion | |
| Control Arm | 1035.6 | 896.58 | 969.89 |
| Prophylaxis With Enoxaparin | 919.7 | 851.19 | 826.97 |
mITT Cohort 1: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 1: Between randomization and Day 42 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 1.30 |
| Enoxaparin | 1.90 |
mITT Cohort 2: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 2: Between randomization and Day 42 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 1.03 |
| Enoxaparin | 1.45 |
mITT Cohort 2: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 2: Between randomization and Day 47 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 4.70 |
| Enoxaparin | 6.02 |
mITT: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT: Between randomization and Day 42 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 0.94 |
| Enoxaparin | 1.45 |
mITT: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT: Between randomization and Day 47 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 4.43 |
| Enoxaparin | 5.99 |
mITT Cohort 1: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, venous thromboembolism (VTE) related death adjudicated by a blinded independent Clinical Events Committee (CEC) between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 1: Between randomization and Day 47 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 5.70 |
| Enoxaparin | 7.18 |
Percentage of participants experiencing at least one major bleeding adjudicated by a blinded independent CEC between randomization (day 1) and up to seven days after discontinuation of all study medication. (NCT01583218)
Timeframe: Between randomization and Day 49 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 0.67 |
| Enoxaparin | 0.57 |
Comparison of number of COVID-19 positive patients who have died within 30 days of starting treatment on each treatment arm (NCT04406389)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intermediate Dose Prophylaxis | 0 |
| Therapeutic Dose Anticoagulation | 2 |
Comparison of length of ICU stay in days between each treatment arm. (NCT04406389)
Timeframe: 6 months
| Intervention | Days (Median) |
|---|---|
| Intermediate Dose Prophylaxis | 25.5 |
| Therapeutic Dose Anticoagulation | 25 |
Comparison of number of documented VTE, arterial thrombosis and microthrombosis events on each treatment arm (NCT04406389)
Timeframe: 6 months
| Intervention | Count of Events (Number) | ||
|---|---|---|---|
| Venous Thromboembolism Events | Arterial Thrombosis Events | Microthrombosis Events | |
| Intermediate Dose Prophylaxis | 1 | 1 | 0 |
| Therapeutic Dose Anticoagulation | 0 | 0 | 1 |
Comparison of major and clinically-relevant non-major bleeding events on each treatment arm, as defined by the International Society of Thrombosis and Haemostasis (ISTH) criteria. (NCT04406389)
Timeframe: 6 months
| Intervention | Count of Events (Number) | |
|---|---|---|
| Major Bleeding Events | Clinically Relevant Non-Major Bleeding Events | |
| Intermediate Dose Prophylaxis | 1 | 1 |
| Therapeutic Dose Anticoagulation | 1 | 2 |
Percentage of participants with Arterial puncture aspiration (NCT02318940)
Timeframe: intraoperative, an average of 1 hour
| Intervention | percentage of participants (Number) |
|---|---|
| Landmark Method | 25 |
| Ultrasound Method | 10 |
Percentage of Participants with successful installation on the first transcutaneous passage of the glass needle (NCT02318940)
Timeframe: intraoperative, an average of 1 hour
| Intervention | percentage of participants (Number) |
|---|---|
| Landmark Method | 18 |
| Ultrasound Method | 42 |
Percentage of participants with successful installation of guide without difficulty in the femoral vein (NCT02318940)
Timeframe: intraoperative, an average of 1 hour
| Intervention | percentage of participants (Number) |
|---|---|
| Landmark Method | 51 |
| Ultrasound Method | 84 |
Number of participants who succeeded in the installation of cvc in one, two, three, four or five attempts. (NCT02318940)
Timeframe: intraoperative, an average of 1 hour
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| first attempt | second attempt | third attempt | fourth attempt | fifth attempt | Unsuccessful cannulation | |
| Landmark Method | 9 | 4 | 6 | 2 | 4 | 24 |
| Ultrasound Method | 21 | 18 | 4 | 0 | 0 | 7 |
5 reviews available for dalteparin and Critical Illness
| Article | Year |
|---|---|
Preventing venous thromboembolism in critically ill patients.
Topics: Clinical Trials as Topic; Critical Illness; Dalteparin; Heparin; Humans; Intensive Care Units; Nadro | 2008 |
Postinjury thromboprophylaxis.
Topics: Anticoagulants; Critical Illness; Enoxaparin; Factor Xa Inhibitors; Fondaparinux; Humans; Incidence; | 2008 |
A bioavailability study in the proposed patient population--with much more needed now.
Topics: Anticoagulants; Antithrombin III; Biological Availability; Critical Care; Critical Illness; Drug Mon | 2003 |
Thrombosis prophylaxis in patient populations with a central venous catheter: a systematic review.
Topics: Anticoagulants; Antineoplastic Agents; Catheterization, Central Venous; Critical Illness; Dalteparin | 2003 |
Life-threatening Hughes-Stovin syndrome: The Yin and Yang of anticoagulation therapy.
Topics: Adrenal Cortex Hormones; Adult; Anticoagulants; Antiphospholipid Syndrome; Behcet Syndrome; Critical | 2016 |
25 trials available for dalteparin and Critical Illness
| Article | Year |
|---|---|
Pharmacokinetic profiles of intravenous versus subcutaneous administration of low molecular weight heparin for thromboprophylaxis in critically ill patients: A randomized controlled trial.
Topics: Anticoagulants; Critical Illness; Heparin, Low-Molecular-Weight; Humans; Nadroparin; Prospective Stu | 2022 |
Pharmacokinetic Comparison of Subcutaneous and Intravenous Nadroparin Administration for Thromboprophylaxis in Critically Ill Patients on Vasopressors.
Topics: Administration, Intravenous; Aged; Anticoagulants; Critical Illness; Factor Xa; Female; Humans; Inje | 2020 |
Citrate anticoagulation for continuous venovenous hemofiltration.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Critical Illness; Female; Hemofiltration; He | 2009 |
Citrate anticoagulation for continuous venovenous hemofiltration.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Critical Illness; Female; Hemofiltration; He | 2009 |
Citrate anticoagulation for continuous venovenous hemofiltration.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Critical Illness; Female; Hemofiltration; He | 2009 |
Citrate anticoagulation for continuous venovenous hemofiltration.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Citric Acid; Critical Illness; Female; Hemofiltration; He | 2009 |
Hemostasis during low molecular weight heparin anticoagulation for continuous venovenous hemofiltration: a randomized cross-over trial comparing two hemofiltration rates.
Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; APACHE; Blood Coagulation; Critical Illness; Cross | 2009 |
Safety of citrate based hemofiltration in critically ill patients at high risk for bleeding: a comparison with nadroparin.
Topics: Anticoagulants; Citric Acid; Cohort Studies; Critical Illness; Erythrocyte Transfusion; Hemofiltrati | 2006 |
An observational study on the effects of nadroparin-based and citrate-based continuous venovenous hemofiltration on calcium metabolism.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Calcium; Calcium Citrate; Chelating Agents; Citrates; Cri | 2007 |
[The drug prevention of postoperative thromboses in patients with critical lower limb ischemia].
Topics: Anticoagulants; Aspirin; Critical Illness; Humans; Ischemia; Leg; Nadroparin; Platelet Aggregation I | 1999 |
Anti-factor Xa level monitoring of low-molecular-weight heparin for prevention of venous thromboembolism in critically ill patients (AXaLPE): protocol of a randomised, open-label controlled clinical trial.
Topics: Anticoagulants; Critical Illness; Enoxaparin; Factor Xa Inhibitors; Heparin; Heparin, Low-Molecular- | 2023 |
Continuous intravenous infusion of enoxaparin controls thrombin formation more than standard subcutaneous administration in critically ill patients. A sub-study of the ENOKSI thromboprophylaxis RCT.
Topics: Anticoagulants; Critical Illness; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Infusions, Intr | 2021 |
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies.
Topics: Anticoagulants; Atorvastatin; COVID-19; COVID-19 Drug Treatment; Critical Illness; Double-Blind Meth | 2020 |
Efficacy of Early Prophylaxis Against Catheter-Associated Thrombosis in Critically Ill Children: A Bayesian Phase 2b Randomized Clinical Trial.
Topics: Adolescent; Anticoagulants; Bayes Theorem; Catheterization, Central Venous; Central Venous Catheters | 2021 |
Age-Dependent Heterogeneity in the Efficacy of Prophylaxis With Enoxaparin Against Catheter-Associated Thrombosis in Critically Ill Children: A Post Hoc Analysis of a Bayesian Phase 2b Randomized Clinical Trial.
Topics: Anticoagulants; Catheterization, Central Venous; Child; Child, Preschool; Critical Illness; Enoxapar | 2021 |
Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Benzamides; Critical Illness; Enoxaparin; Factor Xa | 2019 |
A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: a double-blinded, randomised controlled trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Critical Illness; Dose-Response Relationship, Drug; Double- | 2013 |
A feasible strategy for preventing blood clots in critically ill patients with acute kidney injury (FBI): study protocol for a randomized controlled trial.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Adult; Anticoagulants; Critical Illness; Double-Blind Met | 2014 |
Anti-Factor Xa Activity of Prophylactic Enoxaparin Regimens in Critically Ill Patients.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Anticoagulants; Critical Illness; Dose-Respons | 2016 |
Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Critical Illness; Drug Administration Schedule; Elec | 2010 |
Bioactivity of enoxaparin in critically ill patients with normal renal function.
Topics: Adult; Aged; Anticoagulants; Case-Control Studies; Critical Illness; Enoxaparin; Factor Xa Inhibitor | 2012 |
Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
Topics: Aged; Analysis of Variance; Anticoagulants; Antithrombin III; Body Mass Index; Creatinine; Critical | 2003 |
Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial.
Topics: Aged; Anticoagulants; Critical Illness; Enoxaparin; Female; Humans; Male; Multicenter Studies as Top | 2000 |
Sex differences in thromboprophylaxis of the critically ill: a secondary analysis of a randomized trial.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Heparin; Humans; Male; Pulmonary Embolism; Sex | 2023 |
Heparin-induced thrombocytopenia in medical surgical critical illness.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Platelets; Critical Illness; Dalteparin; Dose- | 2013 |
Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients.
Topics: Aged; Anticoagulants; APACHE; Critical Illness; Dalteparin; Female; Heparin; Humans; Intensive Care | 2015 |
Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Critical Illness; Dalteparin; Female; Humans; Male; Middle | 2008 |
Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Critical Illness; Dalteparin; Female; Humans; Male; Middle | 2008 |
Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Critical Illness; Dalteparin; Female; Humans; Male; Middle | 2008 |
Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Critical Illness; Dalteparin; Female; Humans; Male; Middle | 2008 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
45 other studies available for dalteparin and Critical Illness
| Article | Year |
|---|---|
Trough anti-Xa activity after intermediate dose nadroparin for thrombosis prophylaxis in critically ill patients with COVID-19 and acute kidney injury.
Topics: Acute Kidney Injury; Anticoagulants; COVID-19; Critical Illness; Humans; Nadroparin; Prospective Stu | 2022 |
Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients.
Topics: Anti-Bacterial Agents; Anticoagulants; COVID-19; Critical Illness; Humans; Inflammation; Intensive C | 2023 |
Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients.
Topics: Anti-Bacterial Agents; Anticoagulants; COVID-19; Critical Illness; Humans; Inflammation; Intensive C | 2023 |
Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients.
Topics: Anti-Bacterial Agents; Anticoagulants; COVID-19; Critical Illness; Humans; Inflammation; Intensive C | 2023 |
Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients.
Topics: Anti-Bacterial Agents; Anticoagulants; COVID-19; Critical Illness; Humans; Inflammation; Intensive C | 2023 |
Low and Highly Variable Exposure to Prophylactic LMWH Nadroparin in Critically Ill Patients: Back to the Drawing Board for Prophylactic Dosing?
Topics: Adult; Anticoagulants; Critical Illness; Humans; Nadroparin; Venous Thromboembolism | 2023 |
Strong ion difference and CVVH: Different response during nadroparin versus citrate anticoagulation.
Topics: Acute Kidney Injury; Adult; Aged; Anesthesia; Anions; Anticoagulants; APACHE; Blood Coagulation; Cit | 2018 |
Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia.
Topics: Adult; Amputation, Surgical; Ankle Brachial Index; Anticoagulants; Arteritis; Aspirin; Cardiovascula | 2017 |
Advanced cell therapy with low tissue factor loaded product NestaCell® does not confer thrombogenic risk for critically ill COVID-19 heparin-treated patients.
Topics: Cell- and Tissue-Based Therapy; Clinical Trials as Topic; COVID-19; Critical Illness; Enoxaparin; He | 2022 |
Low-Molecular-Weight Heparin Resistance and Its Viscoelastic Assessment in Critically Ill COVID-19 Patients.
Topics: Anticoagulants; Antithrombins; C-Reactive Protein; COVID-19 Drug Treatment; Critical Illness; Enoxap | 2022 |
Venous thromboembolism prophylaxis in patients hospitalized in medical wards: A real life experience.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Critical Illness; Enoxaparin; Female; Humans; Male; | 2020 |
The impact of protocol-based high-intensity pharmacological thromboprophylaxis on thrombotic events in critically ill COVID-19 patients.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Clinical Protocols; COVID-19; Critical Care; Critica | 2021 |
Anti-Xa levels in critically ill children receiving enoxaparin for venothromboembolism prophylaxis.
Topics: Anticoagulants; Child; Critical Illness; Drug Administration Schedule; Enoxaparin; Humans; Venous Th | 2021 |
Fixed-dose enoxaparin provides efficient DVT prophylaxis in mixed ICU patients despite low anti-Xa levels: A prospective observational cohort study.
Topics: Anticoagulants; Critical Illness; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Intensive Care | 2022 |
Pharmacokinetics of enoxaparin in COVID-19 critically ill patients.
Topics: Anticoagulants; COVID-19; Critical Illness; Enoxaparin; Humans; Retrospective Studies; SARS-CoV-2 | 2021 |
Enoxaparin: Route Cause Analysis.
Topics: Anticoagulants; Blood Coagulation; Child; Critical Illness; Enoxaparin; Humans; Infant; Nutritional | 2017 |
Direct oral anticoagulants for venous thromboembolism prophylaxis in critically ill patients: where do we go from here?
Topics: Anticoagulants; Benzamides; Critical Illness; Enoxaparin; Humans; Pyridines; Venous Thromboembolism | 2019 |
Antifactor Xa levels in critically ill Korean patients receiving enoxaparin for thromboprophylaxis: a prospective observational study.
Topics: Aged; Asian People; Critical Illness; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Female; Fibrinoly | 2013 |
Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis.
Topics: Age Factors; Anticoagulants; Antithrombin III; Critical Illness; Dose-Response Relationship, Drug; D | 2014 |
Prospective Evaluation of Weight-Based Prophylactic Enoxaparin Dosing in Critically Ill Trauma Patients: Adequacy of AntiXa Levels Is Improved.
Topics: Adult; Aged; Anticoagulants; Body Weight; Critical Care; Critical Illness; Drug Administration Sched | 2015 |
Determining the safety of enoxaparin prophylaxis in critically ill patients with severe renal insufficiency - The PACER pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Critical Illness; Enoxaparin; Female; Humans; Male; | 2016 |
Failure of chemical thromboprophylaxis in critically ill medical and surgical patients with sepsis.
Topics: Aged; Anticoagulants; Critical Illness; Enoxaparin; Female; Heparin; Hospitalization; Humans; Incide | 2017 |
IV Versus Subcutaneous Enoxaparin in Critically Ill Infants and Children: Comparison of Dosing, Anticoagulation Quality, Efficacy, and Safety Outcomes.
Topics: Anticoagulants; Child; Child, Preschool; Clinical Protocols; Critical Illness; Drug Administration S | 2017 |
Experience with intravenous enoxaparin in critically ill infants and children.
Topics: Anticoagulants; Child; Child, Preschool; Critical Illness; Enoxaparin; Humans; Infant; Infant, Newbo | 2008 |
Thrombelastography versus AntiFactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients.
Topics: Antibodies; Anticoagulants; Chemoprevention; Critical Illness; Enoxaparin; Factor Xa; Female; Humans | 2009 |
Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit?
Topics: Anticoagulants; Creatinine; Critical Illness; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Female; H | 2010 |
Adequate thromboprophylaxis in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dose-Response Relationship, Drug; Enoxaparin; Factor Xa; Humans; V | 2010 |
Renal function and thromboprophylaxis in critically ill patients.
Topics: Anticoagulants; Critical Illness; Enoxaparin; Humans; Kidney; Kidney Function Tests; Thrombosis | 2010 |
Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients.
Topics: Anticoagulants; Area Under Curve; Critical Illness; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Fem | 2011 |
Life threatening haemorrhagic events associated with the administration of low-molecular-weight-heparin.
Topics: Adult; Aged; Aged, 80 and over; Critical Illness; Enoxaparin; Female; Hemorrhage; Heparin, Low-Molec | 2004 |
Optimal dose of enoxaparin in critically ill trauma and surgical patients.
Topics: Anticoagulants; Critical Illness; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Pro | 2005 |
Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients.
Topics: Adult; Aged; Aged, 80 and over; Antithrombin III; Cohort Studies; Critical Illness; Edema; Enoxapari | 2005 |
The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls.
Topics: Adenosine Diphosphate; Adult; Aged; Anticoagulants; Chondroitin Sulfates; Critical Illness; Daltepar | 1997 |
Effects of dalteparin on anti-Xa activities cannot be predicted in critically ill COVID-19 patients.
Topics: Anticoagulants; COVID-19 Drug Treatment; Critical Illness; Dalteparin; Factor Xa Inhibitors; Heparin | 2022 |
No effect of norepinephrine dose on anti-Xa activity in critically ill patients
.
Topics: Adult; Anticoagulants; Critical Illness; Dalteparin; Factor Xa Inhibitors; Humans; Intensive Care Un | 2020 |
Barriers and challenges in the process of including critically ill patients in clinical studies.
Topics: Adult; Critical Illness; Dalteparin; Female; Fibrinolytic Agents; Humans; Informed Consent; Male; No | 2020 |
Inadequate prophylactic effect of low-molecular weight heparin in critically ill COVID-19 patients.
Topics: Adult; Anticoagulants; Blood Coagulation; Blood Coagulation Disorders; COVID-19 Drug Treatment; Crit | 2020 |
Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients.
Topics: Aged; Anticoagulants; APACHE; COVID-19; Critical Illness; Dalteparin; Female; Humans; Intensive Care | 2020 |
Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis.
Topics: Adult; Aged; Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Hospital Mor | 2013 |
Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
Topics: Anticoagulants; Cost-Benefit Analysis; Critical Illness; Dalteparin; Female; Health Expenditures; He | 2014 |
ACP journal club. Dalteparin was at least as effective as UFH for VTE prevention in critically ill patients, with similar costs.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Health Expenditures; Heparin; Humans; Male; Ve | 2015 |
Event adjudication and data monitoring in an intensive care unit observational study of thromboprophylaxis.
Topics: Anticoagulants; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Critical Illne | 2009 |
Dalteparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Heparin; Humans; Thrombocytopenia; Venous Thrombosis | 2011 |
Dalteparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Heparin; Humans; Incidence; Outcome Assessment, Health | 2011 |
Dalteparin and heparin-induced thrombocytopenia.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Heparin; Humans; Male; Venous Thrombosis | 2011 |
Low-molecular-weight heparin for anticoagulation during continuous venovenous hemofiltration.
Topics: Anticoagulants; Critical Illness; Dalteparin; Drug Monitoring; Hemofiltration; Humans; Renal Insuffi | 2003 |
Monitoring of subcutaneous dalteparin in patients with renal insufficiency under intensive care: an observational study.
Topics: Aged; Anticoagulants; Critical Care; Critical Illness; Dalteparin; Female; Humans; Male; Observation | 2006 |
Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors.
Topics: Aged; Anticoagulants; APACHE; Critical Illness; Dalteparin; Female; Hemorrhage; Humans; Incidence; I | 2008 |